A Phase II trial of pembrolizumab for patients with melanoma or non-small cell lung cancer and untreated brain metastases

BACKGROUND: Immunotherapy targeting the PD-1 axis has activity in several tumor types. We aimed to determine the efficacy and safety of pembrolizumab in patients with untreated brain metastases. Here we present results from a Phase II trial of the PD-1 inhibitor pembrolizumab in patients with new or...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Lancet Oncol
Autori principali: Goldberg, Sarah B., Gettinger, Scott N., Mahajan, Amit, Chiang, Anne C., Herbst, Roy S., Sznol, Mario, Tsiouris, Apostolos John, Cohen, Justine, Vortmeyer, Alexander, Jilaveanu, Lucia, Yu, James, Hegde, Upendra, Speaker, Stephanie, Madura, Matthew, Ralabate, Amanda, Rivera, Angel, Rowen, Elin, Gerrish, Heather, Yao, Xiaopan, Chiang, Veronica, Kluger, Harriet M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5526047/
https://ncbi.nlm.nih.gov/pubmed/27267608
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(16)30053-5
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi